Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.

[1]  B. Brodie,et al.  Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. , 2000, The American journal of cardiology.

[2]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[3]  D. Freimark,et al.  The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. , 1999, Journal of the American College of Cardiology.

[4]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .

[5]  R. Califf,et al.  Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. , 1999, The American journal of cardiology.

[6]  J. Ferguson,et al.  IIb/IIIa receptor blockade in acute myocardial infarction. , 1999, American heart journal.

[7]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[8]  C. Gibson,et al.  Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting , 1999, Annals of Internal Medicine.

[9]  W. Tan,et al.  TIMI flow and surrogate end points: what you see is not always what you get. , 1998, American heart journal.

[10]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[11]  D. Antoniucci,et al.  A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. , 1998, Journal of the American College of Cardiology.

[12]  Stone Gw.  Stenting and IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: An Introduction to the CADILLAC Trial. , 1998 .

[13]  E. Topol.  A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.

[14]  M. Simoons,et al.  A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. , 1997, The New England journal of medicine.

[15]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[16]  J S Martin,et al.  A Comparison of Thrombolytic Therapy with Primary Coronary Angioplasty for Acute Myocardial Infarction , 1996 .

[17]  W. Weaver,et al.  Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. , 1996, Circulation.

[18]  K. Neuhaus,et al.  Thrombolysis and mechanical intervention following myocardial infarction. , 1996, European heart journal.

[19]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[20]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[21]  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[22]  R. Wilcox.  Thrombolysis with tissue plasminogen activator in suspected acute myocardial infarction. The ASSET Study. , 1989, Chest.

[23]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[24]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[25]  A. Jaffe,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. , 1988, Journal of the American College of Cardiology.

[26]  Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. , 1988, JAMA.

[27]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[28]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[29]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[30]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[31]  R. Gabriel.  IgA DEFICIENCY, HYPERTENSION, AND MULTICYSTIC RENAL DISEASE , 1976, The Lancet.